NTQ1062 / Sino Biopharm - LARVOL DELTA

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer (clinicaltrials.gov) - P3 | N=210 | Not yet recruiting | Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical

New P3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical | Active, not recruiting ➔ Completed

Metastases • Trial completion • Oncology • Solid Tumor

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical

New P1 trial • Oncology • Solid Tumor

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical

New P1 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor